Alpelisib is a drug used to treat breast cancer that has certain characteristics (hormone receptor-positive (HR+), human epidermal growth receptor 2-negative (HER2–), PIK3CA-mutated) and that has or has not spread to other organs. This evidence concerns the gene ERBB2 and breast carcinoma.